• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对高磷血症患者使用的两种不同磷酸盐结合剂(盐酸司维拉姆和碳酸钙)进行细胞遗传学分析。

cytogenetic analysis of two different anti-phosphates (sevelamer hydrochloride and calcium carbonate) agents used by patients with hyperphosphatemia.

机构信息

Department of Biology, Faculty of Science and Letters, Çukurova University, Adana, Turkey.

出版信息

Drug Chem Toxicol. 2023 Nov;46(4):699-707. doi: 10.1080/01480545.2022.2083150. Epub 2022 Jun 7.

DOI:10.1080/01480545.2022.2083150
PMID:35670083
Abstract

Sevelamer hydrochloride (SH) and calcium carbonate (CaCO) are two agents included in the phosphate-binding group which are frequently prescribed in the treatment of patients with hyperphosphatemia. However, there are no satisfactory studies on the genotoxic effects of SH in vitro. This study was conducted to reveal the genotoxic and/or cytotoxic potential of these two drugs in cultured human peripheral lymphocytes. Human peripheral lymphocytes were treated with SH and CaCO at sublethal concentrations for 24 or 48 h for micronucleus assay and 1 h in the comet assay. CaCO and SH stimulated a slight increase in micronucleus formation however this increase was not significant compared to the control group. According to the findings of the comet test, only one concentration of the SH caused significant DNA damage (2 mg/ml, 48 h) whereas CaCO did not cause important DNA breakage. No significant oxidative damage or anti-radical effect caused by test substances was observed on the pure pBR322 plasmid DNA in a cell-free medium. Also, it was found that the drugs were devoid of mutagenic activity in the Ames test, but had a weak cytotoxic effect. Both test substances, particularly SH, significantly reduced the nuclear division index compared to the control group. In conclusion, the cytotoxic effect of SH was evident on the basis of tests and slightly higher than CaCO.

摘要

盐酸司维拉姆(SH)和碳酸钙(CaCO)是两种常用于治疗高磷血症患者的磷结合剂药物。然而,目前尚无关于 SH 在体外的遗传毒性作用的满意研究。本研究旨在揭示这两种药物在培养的人外周血淋巴细胞中的遗传毒性和/或细胞毒性潜力。将人外周血淋巴细胞用亚致死浓度的 SH 和 CaCO 处理 24 或 48 小时,进行微核试验,用彗星试验处理 1 小时。CaCO 和 SH 轻微刺激微核形成增加,但与对照组相比,这种增加并不显著。根据彗星试验的结果,只有 SH 的一个浓度(2mg/ml,48 小时)导致明显的 DNA 损伤,而 CaCO 没有导致重要的 DNA 断裂。在无细胞培养基中,纯 pBR322 质粒 DNA 上未观察到测试物质引起的明显氧化损伤或自由基清除作用。此外,还发现这些药物在 Ames 试验中没有致突变活性,但具有较弱的细胞毒性作用。与对照组相比,两种测试物质,特别是 SH,显著降低了核分裂指数。总之,基于这些测试,SH 的细胞毒性作用明显,略高于 CaCO。

相似文献

1
cytogenetic analysis of two different anti-phosphates (sevelamer hydrochloride and calcium carbonate) agents used by patients with hyperphosphatemia.对高磷血症患者使用的两种不同磷酸盐结合剂(盐酸司维拉姆和碳酸钙)进行细胞遗传学分析。
Drug Chem Toxicol. 2023 Nov;46(4):699-707. doi: 10.1080/01480545.2022.2083150. Epub 2022 Jun 7.
2
Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.在血液透析患者中,单独使用或与碳酸钙联合使用时,盐酸司维拉姆与考来替胺的比较。
Ther Apher Dial. 2008 Apr;12(2):126-32. doi: 10.1111/j.1744-9987.2008.00557.x.
3
Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients.司维拉姆与碳酸钙联合治疗对日本血液透析患者高磷血症的疗效
Ther Apher Dial. 2005 Aug;9(4):347-51. doi: 10.1111/j.1744-9987.2005.00295.x.
4
The real-world dose-relativity of sevelamer hydrochloride and lanthanum carbonate monotherapy in patients with end-stage renal disease.盐酸司维拉姆和碳酸镧单药治疗终末期肾病患者的真实世界剂量相关性
Adv Ther. 2013 Dec;30(12):1100-10. doi: 10.1007/s12325-013-0077-5. Epub 2013 Dec 5.
5
Phosphate binders in CKD: chalking out the differences.慢性肾脏病中的磷酸盐结合剂:差异分析。
Pediatr Nephrol. 2010 Mar;25(3):385-94. doi: 10.1007/s00467-009-1329-0. Epub 2009 Nov 7.
6
Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis.盐酸司维拉姆和碳酸镧对日本血液透析患者疗效及安全性的随机交叉研究。
Ther Apher Dial. 2012 Aug;16(4):341-9. doi: 10.1111/j.1744-9987.2012.01071.x. Epub 2012 May 11.
7
Pre-treatment of dairy and breast milk with sevelamer hydrochloride and sevelamer carbonate to reduce phosphate.用盐酸司维拉姆和碳酸司维拉姆对奶制品和母乳进行预处理,以降低磷酸盐。
Perit Dial Int. 2013 Sep-Oct;33(5):565-72. doi: 10.3747/pdi.2012.00063. Epub 2013 May 1.
8
Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.碳酸司维拉姆与盐酸司维拉姆的比较:代谢性酸中毒风险及临床意义
Pharmacotherapy. 2009 May;29(5):554-61. doi: 10.1592/phco.29.5.554.
9
Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.碳酸镧治疗透析患者高磷血症的成本效果分析:一个加拿大支付方视角。
Clin Ther. 2012 Jul;34(7):1531-43. doi: 10.1016/j.clinthera.2012.06.006. Epub 2012 Jun 27.
10
A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.终末期肾病患者接受血液透析时磷酸盐结合剂的比较研究。
Saudi J Kidney Dis Transpl. 2014 May;25(3):530-8. doi: 10.4103/1319-2442.132167.

引用本文的文献

1
Therapeutic effectiveness and safety profile of lanthanum carbonate in conjunction with calcium carbonate for managing hyperphosphatemia in hemodialysis patients: a meta-analysis of randomized controlled trials.碳酸镧联合碳酸钙治疗血液透析患者高磷血症的疗效及安全性分析:一项随机对照试验的荟萃分析
Am J Transl Res. 2024 Nov 15;16(11):6980-6990. doi: 10.62347/WXBL2590. eCollection 2024.